Regeneron Pharmaceuticals, Inc. (0R2M.L)
USD 732.14
(-1.06%)
USD 732.14
(-1.06%)
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2023 | 33.08 Billion USD | 13.23% |
| 2022 | 29.21 Billion USD | 14.86% |
| 2021 | 25.43 Billion USD | 48.19% |
| 2020 | 17.16 Billion USD | 15.93% |
| 2019 | 14.8 Billion USD | 26.17% |
| 2018 | 11.73 Billion USD | 33.89% |
| 2017 | 8.76 Billion USD | 25.68% |
| 2016 | 6.97 Billion USD | 24.32% |
| 2015 | 5.6 Billion USD | 44.87% |
| 2014 | 3.87 Billion USD | 31.2% |
| 2013 | 2.95 Billion USD | 41.84% |
| 2012 | 2.08 Billion USD | 57.19% |
| 2011 | 1.32 Billion USD | 21.49% |
| 2010 | 1.08 Billion USD | 46.98% |
| 2009 | 741.2 Million USD | 10.62% |
| 2008 | 670.03 Million USD | -28.43% |
| 2007 | 936.25 Million USD | 60.02% |
| 2006 | 585.09 Million USD | 38.16% |
| 2005 | 423.5 Million USD | -10.49% |
| 2004 | 473.1 Million USD | -1.34% |
| 2003 | 479.55 Million USD | 22.47% |
| 2002 | 391.57 Million USD | -20.96% |
| 2001 | 495.39 Million USD | 137.86% |
| 2000 | 208.27 Million USD | 52.02% |
| 1999 | 137 Million USD | -12.68% |
| 1998 | 156.9 Million USD | -6.83% |
| 1997 | 168.4 Million USD | 22.38% |
| 1996 | 137.6 Million USD | 46.7% |
| 1995 | 93.8 Million USD | -0.42% |
| 1994 | 94.2 Million USD | -19.9% |
| 1993 | 117.6 Million USD | 20.12% |
| 1992 | 97.9 Million USD | -14.12% |
| 1991 | 114 Million USD | 348.82% |
| 1990 | 25.4 Million USD | 0.0% |
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2024 Q1 | 34.36 Billion USD | 3.9% |
| 2024 Q3 | 37.44 Billion USD | 3.76% |
| 2024 Q2 | 36.08 Billion USD | 5.0% |
| 2023 Q1 | 30.05 Billion USD | 2.89% |
| 2023 Q2 | 30.65 Billion USD | 1.99% |
| 2023 FY | 33.08 Billion USD | 13.23% |
| 2023 Q3 | 32.16 Billion USD | 4.91% |
| 2023 Q4 | 33.08 Billion USD | 2.85% |
| 2022 Q2 | 27.2 Billion USD | 3.25% |
| 2022 Q4 | 29.21 Billion USD | 5.55% |
| 2022 FY | 29.21 Billion USD | 14.86% |
| 2022 Q1 | 26.34 Billion USD | 3.59% |
| 2022 Q3 | 27.67 Billion USD | 1.73% |
| 2021 Q3 | 23.67 Billion USD | 10.17% |
| 2021 Q4 | 25.43 Billion USD | 7.45% |
| 2021 Q1 | 17.77 Billion USD | 3.55% |
| 2021 FY | 25.43 Billion USD | 48.19% |
| 2021 Q2 | 21.48 Billion USD | 20.9% |
| 2020 FY | 17.16 Billion USD | 15.93% |
| 2020 Q4 | 17.16 Billion USD | 6.71% |
| 2020 Q1 | 15.75 Billion USD | 6.43% |
| 2020 Q2 | 14.42 Billion USD | -8.43% |
| 2020 Q3 | 16.08 Billion USD | 11.47% |
| 2019 Q3 | 13.93 Billion USD | 5.81% |
| 2019 Q4 | 14.8 Billion USD | 6.21% |
| 2019 Q2 | 13.17 Billion USD | 2.48% |
| 2019 Q1 | 12.85 Billion USD | 9.55% |
| 2019 FY | 14.8 Billion USD | 26.17% |
| 2018 Q3 | 10.8 Billion USD | 8.58% |
| 2018 Q1 | 9.37 Billion USD | 6.94% |
| 2018 FY | 11.73 Billion USD | 33.89% |
| 2018 Q2 | 9.95 Billion USD | 6.18% |
| 2018 Q4 | 11.73 Billion USD | 8.6% |
| 2017 FY | 8.76 Billion USD | 25.68% |
| 2017 Q3 | 8.7 Billion USD | 7.34% |
| 2017 Q4 | 8.76 Billion USD | 0.72% |
| 2017 Q1 | 7.81 Billion USD | 12.1% |
| 2017 Q2 | 8.1 Billion USD | 3.7% |
| 2016 Q4 | 6.97 Billion USD | 2.13% |
| 2016 FY | 6.97 Billion USD | 24.32% |
| 2016 Q2 | 6.2 Billion USD | 5.09% |
| 2016 Q3 | 6.82 Billion USD | 10.04% |
| 2016 Q1 | 5.9 Billion USD | 5.27% |
| 2015 Q2 | 4.52 Billion USD | 7.82% |
| 2015 Q1 | 4.19 Billion USD | 8.44% |
| 2015 Q4 | 5.6 Billion USD | 8.22% |
| 2015 Q3 | 5.18 Billion USD | 14.49% |
| 2015 FY | 5.6 Billion USD | 44.87% |
| 2014 Q4 | 3.87 Billion USD | 3.54% |
| 2014 FY | 3.87 Billion USD | 31.2% |
| 2014 Q1 | 3.26 Billion USD | 10.48% |
| 2014 Q2 | 3.45 Billion USD | 6.0% |
| 2014 Q3 | 3.73 Billion USD | 8.2% |
| 2013 Q3 | 2.64 Billion USD | 11.02% |
| 2013 Q2 | 2.37 Billion USD | 4.49% |
| 2013 Q1 | 2.27 Billion USD | 9.4% |
| 2013 FY | 2.95 Billion USD | 41.84% |
| 2013 Q4 | 2.95 Billion USD | 11.76% |
| 2012 Q4 | 2.08 Billion USD | 25.28% |
| 2012 Q2 | 1.45 Billion USD | 7.95% |
| 2012 Q1 | 1.35 Billion USD | 2.01% |
| 2012 FY | 2.08 Billion USD | 57.19% |
| 2012 Q3 | 1.66 Billion USD | 13.94% |
| 2011 Q1 | 1.07 Billion USD | -1.39% |
| 2011 Q4 | 1.32 Billion USD | 34.64% |
| 2011 FY | 1.32 Billion USD | 21.49% |
| 2011 Q2 | 1.04 Billion USD | -2.55% |
| 2011 Q3 | 983.03 Million USD | -6.1% |
| 2010 Q1 | 787.15 Million USD | 6.2% |
| 2010 Q2 | 790.64 Million USD | 0.44% |
| 2010 Q3 | 942.43 Million USD | 19.2% |
| 2010 Q4 | 1.08 Billion USD | 15.6% |
| 2010 FY | 1.08 Billion USD | 46.98% |
| 2009 Q4 | 741.2 Million USD | -0.13% |
| 2009 Q1 | 681.42 Million USD | 1.7% |
| 2009 Q3 | 742.19 Million USD | -0.02% |
| 2009 FY | 741.2 Million USD | 10.62% |
| 2009 Q2 | 742.34 Million USD | 8.94% |
| 2008 FY | 670.03 Million USD | -28.43% |
| 2008 Q2 | 851.22 Million USD | -8.56% |
| 2008 Q3 | 825.89 Million USD | -2.98% |
| 2008 Q4 | 670.03 Million USD | -18.87% |
| 2008 Q1 | 930.87 Million USD | -0.57% |
| 2007 Q2 | 597.85 Million USD | -0.59% |
| 2007 Q3 | 573.09 Million USD | -4.14% |
| 2007 Q4 | 936.25 Million USD | 63.37% |
| 2007 FY | 936.25 Million USD | 60.02% |
| 2007 Q1 | 601.43 Million USD | 2.79% |
| 2006 Q3 | 355.18 Million USD | -6.12% |
| 2006 Q1 | 402.08 Million USD | -5.06% |
| 2006 FY | 585.09 Million USD | 38.16% |
| 2006 Q2 | 378.33 Million USD | -5.91% |
| 2006 Q4 | 585.09 Million USD | 64.73% |
| 2005 Q4 | 423.5 Million USD | 1.01% |
| 2005 Q3 | 419.27 Million USD | -6.19% |
| 2005 Q2 | 446.94 Million USD | -4.96% |
| 2005 Q1 | 470.29 Million USD | -0.6% |
| 2005 FY | 423.5 Million USD | -10.49% |
| 2004 Q3 | 472.68 Million USD | -3.17% |
| 2004 Q2 | 488.17 Million USD | -3.56% |
| 2004 FY | 473.1 Million USD | -1.34% |
| 2004 Q4 | 473.1 Million USD | 0.09% |
| 2004 Q1 | 506.17 Million USD | 5.55% |
| 2003 Q2 | 395.54 Million USD | -8.11% |
| 2003 FY | 479.55 Million USD | 22.47% |
| 2003 Q4 | 479.55 Million USD | -4.19% |
| 2003 Q3 | 500.5 Million USD | 26.53% |
| 2003 Q1 | 430.44 Million USD | 9.93% |
| 2002 Q3 | 418.59 Million USD | -4.96% |
| 2002 Q4 | 391.57 Million USD | -6.45% |
| 2002 Q1 | 471.86 Million USD | -4.75% |
| 2002 Q2 | 440.45 Million USD | -6.66% |
| 2002 FY | 391.57 Million USD | -20.96% |
| 2001 Q4 | 495.39 Million USD | 55.49% |
| 2001 FY | 495.39 Million USD | 137.86% |
| 2001 Q1 | 349.18 Million USD | 67.66% |
| 2001 Q2 | 336.29 Million USD | -3.69% |
| 2001 Q3 | 318.61 Million USD | -5.26% |
| 2000 FY | 208.27 Million USD | 52.02% |
| 2000 Q1 | 132.03 Million USD | -3.62% |
| 2000 Q3 | 216.31 Million USD | 7.03% |
| 2000 Q2 | 202.11 Million USD | 53.08% |
| 2000 Q4 | 208.27 Million USD | -3.72% |
| 1999 Q1 | 149.3 Million USD | -4.84% |
| 1999 FY | 137 Million USD | -12.68% |
| 1999 Q3 | 134.4 Million USD | -3.86% |
| 1999 Q2 | 139.8 Million USD | -6.36% |
| 1999 Q4 | 137 Million USD | 1.93% |
| 1998 Q1 | 161.4 Million USD | -4.16% |
| 1998 Q2 | 165.1 Million USD | 2.29% |
| 1998 Q3 | 162.4 Million USD | -1.64% |
| 1998 Q4 | 156.9 Million USD | -3.39% |
| 1998 FY | 156.9 Million USD | -6.83% |
| 1997 Q1 | 129.1 Million USD | -6.18% |
| 1997 FY | 168.4 Million USD | 22.38% |
| 1997 Q3 | 164.7 Million USD | -3.12% |
| 1997 Q4 | 168.4 Million USD | 2.25% |
| 1997 Q2 | 170 Million USD | 31.68% |
| 1996 Q1 | 86.2 Million USD | -8.1% |
| 1996 Q4 | 137.6 Million USD | 5.36% |
| 1996 Q3 | 130.6 Million USD | -6.25% |
| 1996 FY | 137.6 Million USD | 46.7% |
| 1996 Q2 | 139.3 Million USD | 61.6% |
| 1995 Q1 | 86.1 Million USD | -8.6% |
| 1995 Q3 | 74.2 Million USD | -11.03% |
| 1995 Q4 | 93.8 Million USD | 26.42% |
| 1995 Q2 | 83.4 Million USD | -3.14% |
| 1995 FY | 93.8 Million USD | -0.42% |
| 1994 Q2 | 105.7 Million USD | -0.28% |
| 1994 Q1 | 106 Million USD | -9.86% |
| 1994 FY | 94.2 Million USD | -19.9% |
| 1994 Q4 | 94.2 Million USD | -3.29% |
| 1994 Q3 | 97.4 Million USD | -7.85% |
| 1993 Q3 | 125.9 Million USD | 52.79% |
| 1993 FY | 117.6 Million USD | 20.12% |
| 1993 Q2 | 82.4 Million USD | -9.05% |
| 1993 Q1 | 90.6 Million USD | -7.46% |
| 1993 Q4 | 117.6 Million USD | -6.59% |
| 1992 Q4 | 97.9 Million USD | -6.23% |
| 1992 Q3 | 104.4 Million USD | -3.96% |
| 1992 Q2 | 108.7 Million USD | -3.12% |
| 1992 Q1 | 112.2 Million USD | -1.58% |
| 1992 FY | 97.9 Million USD | -14.12% |
| 1991 Q3 | 114 Million USD | -1.04% |
| 1991 FY | 114 Million USD | 348.82% |
| 1991 Q2 | 115.2 Million USD | 0.0% |
| 1991 Q4 | 114 Million USD | 0.0% |
| 1990 Q4 | 25.4 Million USD | 0.0% |
| 1990 FY | 25.4 Million USD | 0.0% |
| Name | Total Assets | Total Assets Difference |
|---|---|---|
| Editas Medicine, Inc. | 499.15 Million USD | -6527.267% |
| Dynavax Technologies Corporation | 997.09 Million USD | -3217.654% |
| Supernus Pharmaceuticals, Inc. | 1.4 Billion USD | -2247.817% |
| Perrigo Company plc | 10.8 Billion USD | -206.04% |
| Illumina, Inc. | 10.11 Billion USD | -227.17% |
| Thermo Fisher Scientific Inc. | 98.72 Billion USD | 66.493% |
| Iovance Biotherapeutics, Inc. | 780.35 Million USD | -4139.144% |
| Walgreens Boots Alliance, Inc. | 81.03 Billion USD | 59.179% |
| IQVIA Holdings Inc. | 26.68 Billion USD | -23.984% |
| Heron Therapeutics, Inc. | 222.5 Million USD | -14767.105% |
| Unity Biotechnology, Inc. | 65.69 Million USD | -50258.045% |
| Waters Corporation | 4.62 Billion USD | -614.961% |
| Biogen Inc. | 26.84 Billion USD | -23.228% |
| Sangamo Therapeutics, Inc. | 165.32 Million USD | -19909.799% |
| Evolus, Inc. | 188.99 Million USD | -17402.937% |
| Adicet Bio, Inc. | 207.29 Million USD | -15858.031% |
| Cara Therapeutics, Inc. | 125.84 Million USD | -26186.672% |
| bluebird bio, Inc. | 619.16 Million USD | -5242.746% |
| Esperion Therapeutics, Inc. | 205.79 Million USD | -15974.268% |
| FibroGen, Inc. | 423.52 Million USD | -7710.61% |
| Agilent Technologies, Inc. | 10.76 Billion USD | -207.351% |
| Corbus Pharmaceuticals Holdings, Inc. | 28.27 Million USD | -116905.306% |
| Homology Medicines, Inc. | 47.05 Million USD | -70198.149% |
| Geron Corporation | 394.07 Million USD | -8294.371% |
| Alnylam Pharmaceuticals, Inc. | 3.82 Billion USD | -763.74% |
| Amicus Therapeutics, Inc. | 777.88 Million USD | -4152.61% |
| Myriad Genetics, Inc. | 1.19 Billion USD | -2659.673% |
| Viking Therapeutics, Inc. | 368.49 Million USD | -8877.231% |
| Intellia Therapeutics, Inc. | 1.3 Billion USD | -2442.72% |
| Zoetis Inc. | 14.28 Billion USD | -131.557% |
| Abeona Therapeutics Inc. | 64 Million USD | -51586.198% |
| Mettler-Toledo International Inc. | 3.35 Billion USD | -885.834% |
| BioMarin Pharmaceutical Inc. | 6.84 Billion USD | -383.515% |
| Vertex Pharmaceuticals Incorporated | 22.73 Billion USD | -45.534% |
| Kala Pharmaceuticals, Inc. | 55.94 Million USD | -59025.632% |
| Ionis Pharmaceuticals, Inc. | 2.99 Billion USD | -1006.335% |
| Atara Biotherapeutics, Inc. | 165.5 Million USD | -19887.553% |
| Verastem, Inc. | 149.71 Million USD | -21995.005% |
| Nektar Therapeutics | 398.03 Million USD | -8210.919% |
| Axsome Therapeutics, Inc. | 588.23 Million USD | -5523.627% |
| Aclaris Therapeutics, Inc. | 197.4 Million USD | -16657.529% |
| Sarepta Therapeutics, Inc. | 3.26 Billion USD | -913.308% |
| OPKO Health, Inc. | 2.01 Billion USD | -1544.392% |
| Exelixis, Inc. | 2.94 Billion USD | -1024.276% |
| Neurocrine Biosciences, Inc. | 3.25 Billion USD | -917.414% |
| Corcept Therapeutics Incorporated | 621.51 Million USD | -5222.493% |
| Anavex Life Sciences Corp. | 154.38 Million USD | -21326.943% |
| uniQure N.V. | 831.68 Million USD | -3877.472% |
| Imunon, Inc. | 21.91 Million USD | -150826.617% |
| Blueprint Medicines Corporation | 1.04 Billion USD | -3052.747% |
| Insmed Incorporated | 1.32 Billion USD | -2387.538% |
| Halozyme Therapeutics, Inc. | 1.73 Billion USD | -1808.543% |
| Agios Pharmaceuticals, Inc. | 937.11 Million USD | -3429.993% |
| TG Therapeutics, Inc. | 329.58 Million USD | -9936.864% |
| Incyte Corporation | 6.78 Billion USD | -387.757% |
| Emergent BioSolutions Inc. | 1.83 Billion USD | -1702.834% |